However, the more current and clinically translatable MB stratification is based on molecular subtypes, which include SHH-activated (both TP53-wildtype and TP53-mutant groups) with an intermediate prognosis, WNT-activated with a good prognosis, and non-WNT/non-SHH (formerly group 3 and group 4 MBs) with a poorer prognosis [6]. This evidence concerns the gene SHH and Mobius syndrome.